Enovis (NYSE:ENOV) CEO Purchases $249,620.25 in Stock

Enovis Corporation (NYSE:ENOV) CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction on Friday, September 4th. The stock was purchased at an average cost of $19.15 per share, with a total value of $249,620.25. Following the completion of the purchase, the chief executive officer directly owned 247,077 shares in the company, valued at $4,731,524.55. This trade represents a 5.57% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Enovis Trading Up 0.1%

Shares of Enovis stock opened at $18.58 on Monday. Enovis Corporation has a fifty-two week low of $18.52 and a fifty-two week high of $34.28. The business’s fifty day moving average is $25.50 and its two-hundred day moving average is $24.22. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. The firm has a market cap of $1.07 billion, a PE ratio of -0.96 and a beta of 1.31.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same period in the prior year, the firm posted $0.79 earnings per share. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current year.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

Institutional Investors Weigh In On Enovis

Institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its stake in shares of Enovis by 1.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock valued at $90,156,000 after acquiring an additional 51,201 shares during the period. Rubric Capital Management LP purchased a new stake in Enovis during the 3rd quarter worth $83,435,000. Paradigm Capital Management Inc. NY boosted its position in Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after purchasing an additional 732,917 shares during the period. River Road Asset Management LLC increased its holdings in Enovis by 3.2% in the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after purchasing an additional 46,289 shares in the last quarter. Finally, Private Management Group Inc. raised its position in Enovis by 38.8% in the second quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock valued at $28,257,000 after purchasing an additional 381,705 shares during the period. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ENOV. BMO Capital Markets set a $27.00 price target on shares of Enovis in a research report on Tuesday, September 1st. Canaccord Genuity Group decreased their price target on shares of Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 17th. Evercore set a $32.00 price objective on shares of Enovis in a research note on Monday, July 6th. BTIG Research dropped their price objective on Enovis from $40.00 to $36.00 and set a “buy” rating for the company in a report on Tuesday, September 1st. Finally, Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $40.38.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.